CN116194143A - 中性粒细胞驱动的炎症性病理的治疗方法 - Google Patents

中性粒细胞驱动的炎症性病理的治疗方法 Download PDF

Info

Publication number
CN116194143A
CN116194143A CN202180059193.6A CN202180059193A CN116194143A CN 116194143 A CN116194143 A CN 116194143A CN 202180059193 A CN202180059193 A CN 202180059193A CN 116194143 A CN116194143 A CN 116194143A
Authority
CN
China
Prior art keywords
therapeutic peptide
seq
multivalent
neutrophil
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180059193.6A
Other languages
English (en)
Chinese (zh)
Inventor
L·L·埃金克
J·K·胡伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wild Boar Bioscience Co ltd
Original Assignee
Susavian Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Susavian Biosciences filed Critical Susavian Biosciences
Publication of CN116194143A publication Critical patent/CN116194143A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180059193.6A 2020-07-28 2021-06-24 中性粒细胞驱动的炎症性病理的治疗方法 Pending CN116194143A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063057741P 2020-07-28 2020-07-28
US63/057,741 2020-07-28
PCT/US2021/038999 WO2022026092A2 (en) 2020-07-28 2021-06-24 Method of treatment of neutrophil-driven inflammatory pathologies

Publications (1)

Publication Number Publication Date
CN116194143A true CN116194143A (zh) 2023-05-30

Family

ID=80038122

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180059193.6A Pending CN116194143A (zh) 2020-07-28 2021-06-24 中性粒细胞驱动的炎症性病理的治疗方法

Country Status (7)

Country Link
US (1) US20230285505A1 (enExample)
EP (1) EP4181942A4 (enExample)
JP (1) JP2023536815A (enExample)
CN (1) CN116194143A (enExample)
AU (1) AU2021318793A1 (enExample)
CA (1) CA3185526A1 (enExample)
WO (1) WO2022026092A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1768650T3 (pl) * 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
WO2023183059A1 (en) * 2022-03-24 2023-09-28 Susavion Biosciences, Inc. Method of treatment of neutrophil-driven inflammatory pathologies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087793A2 (en) * 2004-02-05 2005-09-22 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
US8460697B2 (en) * 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
ES2316312B1 (es) * 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
WO2013096829A2 (en) * 2011-12-22 2013-06-27 Arizona Biomedical Research Commission Activation of cellular assault processes in the treatment of glioblastoma multiforme
US9155796B2 (en) * 2012-12-04 2015-10-13 Susavion Biosciences, Inc. Hydrogels with covalently linked polypeptides
CA2971471C (en) * 2014-12-19 2023-04-18 Susavion Biosciences, Inc. Immunotherapy treatments and compositions
EP3288576A4 (en) * 2015-04-27 2019-01-16 Susavion Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND PERSISTENT VIRUS INFECTIONS
US10350260B2 (en) * 2015-04-27 2019-07-16 Susavion Biosciences, Inc. Compositions and methods for treating cancer and persistent viral infections
AU2019205279A1 (en) * 2018-01-08 2020-07-30 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides

Also Published As

Publication number Publication date
US20230285505A1 (en) 2023-09-14
JP2023536815A (ja) 2023-08-30
CA3185526A1 (en) 2022-02-03
EP4181942A4 (en) 2024-10-02
WO2022026092A2 (en) 2022-02-03
AU2021318793A1 (en) 2023-02-09
WO2022026092A3 (en) 2022-03-03
WO2022026092A9 (en) 2022-04-28
EP4181942A2 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
Wang et al. Anti-ferroptosis exosomes engineered for targeting M2 microglia to improve neurological function in ischemic stroke
Li et al. Calcitonin gene-related peptide inhibits the cardiac fibroblasts senescence in cardiac fibrosis via up-regulating klotho expression
RU2429004C2 (ru) Способы регуляции медиаторов воспаления и пептиды, используемые в них
Ahn et al. Transient receptor potential channel TRPV4 mediates TGF-β1-induced differentiation of human ventricular fibroblasts
Zhang et al. Mitigation effect of an FGF-2 peptide on acute gastrointestinal syndrome after high-dose ionizing radiation
US20140322226A1 (en) Acth for treatment of acute respiratory distress syndrome
CA2723270C (en) Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
US20230285505A1 (en) Method of treatment of neutrophil-driven inflammatory pathologies
JP2019523293A (ja) 処置の方法
JP2019116487A (ja) 脂質動員特性を有する糖タンパク質およびその治療的使用法
Luo et al. Alterations in the microenvironment and the effects produced of TRPV5 in osteoporosis
US20200246428A1 (en) Zag-derived peptide and use thereof
Kawai et al. Prevention of skeletal muscle atrophy in vitro using anti-ubiquitination oligopeptide carried by atelocollagen
AU2015374240B2 (en) Compositions and methods for delivering lypophilic agents to dental pulp and for enhancing dentin production
HK40090910A (en) Method of treatment of neutrophil-driven inflammatory pathologies
CN119925565A (zh) 一种多肽在制备治疗银屑病药物中的应用
US20260055139A1 (en) Method of treatment of neutrophil-driven inflammatory pathologies
US20250222064A1 (en) Method of treatment of neutrophil-driven inflammatory pathologies
CN119546297A (zh) 用于抑制免疫应答的到手香提取物
US10443059B2 (en) Pharmaceutical composition and method for reducing scar formation
아지즈 GPCR19 agonist (TDCA) efficacy and mode of action in atopic dermatitis and rosacea
Mina Exploiting metabolic and molecular alterations as therapeutic targets for skeletal muscle atrophy in inflammatory diseases
Popov Development of inhaled CaSR NAMs for the treatment of pulmonary disorders
Chen et al. Cadherin-26 drives macrophage alternative activation via suppressing STUB1-mediated IL-4Rα ubiquitination in asthma
del Río Oliva Targeting the immunoproteasome and VCP/p97 in autoimmune disorders and viral infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40090910

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20241206

Address after: Arizona, USA

Applicant after: Wild Boar Bioscience Co.,Ltd.

Country or region after: U.S.A.

Address before: Arizona, USA

Applicant before: Susavian Biosciences

Country or region before: U.S.A.